Evidence map›Paper›PMID 39267117›Full record

ArticleWorld journal of surgical oncology2024

RAS mutation associated with short surgically controllable period in colorectal liver metastases: a retrospective study.

Sono Ito, Takeshi Takamoto, Satoshi Nara, Daisuke Ban, Takahiro Mizui, Hiroshi Nagata, Yasuyuki Takamizawa, Konosuke Moritani, Shunsuke Tsukamoto, Yukihide Kanemitsu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sono ItoDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Takeshi TakamotoDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan. ttakamot@ncc.go.jp.
Satoshi NaraDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Daisuke BanDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Takahiro MizuiDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Hiroshi NagataDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Yasuyuki TakamizawaDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Konosuke MoritaniDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Shunsuke TsukamotoDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Yukihide KanemitsuDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Yusuke KinugasaDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, 113-8519, Japan.
Minoru EsakiDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic implications of the RAS status in colorectal cancer liver metastasis (CRLM) remain unclear. This study investigated the prognostic significance of RAS status after curative hepatectomy, focusing on surgical controllability.

methodsThis retrospective study included liver-only CRLM patients who underwent the first hepatectomy between 2015 and 2022 at the National Cancer Center Hospital. Recurrence-free survival (RFS), surgically controllable period (SCP), and overall survival (OS) were compared between RAS wild-type (RAS-wt) and mutant (RAS-mt) patients. Multivariate analyses were conducted to identify independent prognostic factors for each outcome and independent risk factors for less than 1 year SCP.

resultsA total of 150 patients were evaluated, comprising 63 patients with RAS-mt status. There was no significant difference in RFS between RAS-mt and RAS-wt (7.00 vs. 8.03 months, p = 0.48). RAS-mt patients exhibited worse SCP (11.80 vs.21.13 months, p < 0.001) and OS (44.03 vs. 70.03 months, p < 0.001) compared to RAS-wt. Multivariate analysis identified RAS-mt as an independent prognostic factor for both OS (hazard ratio [HR]: 3.37, p < 0.001) and SCP (HR: 2.20, p < 0.001), and as an independent risk factor for less than 1 year of SCP (odds ratio, 2.31; p = 0.03).

conclusionsCRLM with RAS mutations should be considered for strict surgical indications with preoperative chemotherapy and thorough examination, considering the possibility of short SCP.

Indexed as

Colorectal NeoplasmsHepatectomyLiver NeoplasmsMutationAdultAgedBiomarkers, TumorFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival RateBiomarkers, TumorColorectal cancerLiver metastasisNeoadjuvant chemotherapyRASSurgically controllable period

Identifiers

PMID39267117
PMCPMC11391794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.